在Toxoplasma gondii中挽救皮里米丁作为新治疗的目标
Hamza A A Elati1,2, Amber L Goerner3, Bruno Martorelli Di Genova3
1School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Frontiers in cellular and infection microbiology
|January 1, 2024
概括
研究人员确定了一种新的毒素菌的药物标,即Toxoplasma gondii中的尿素/尿素转运体1 (TgUUT1). 针对TgUUT1的新型化pyrimidines显示出优越的疗效比目前的治疗毒素菌.
科学领域:
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 毒素菌会带来很大的风险,特别是在免疫力低下的人和怀孕期间.
- 治疗选择有限,需要开发新的治疗策略.
- 针对原生动物中的核酸代谢途径是新抗原生动物药物的有希望的途径.
研究的目的:
- 调查基菌中的胺救援途径,作为潜在的药物标.
- 识别和描述负责 uracil 和尿素吸收的载体.
- 评估新型化胺衍生物作为抗毒素菌剂的疗效.
主要方法:
- 进行了放射性标记核和核吸收试验.
- 动力分析和竞争性抑制研究被用来描述载体特性.
- 化皮里米丁的抗寄生虫活性在体外和体内被评估.
主要成果:
- *毒素菌*通过单个载体,即指定尿素/尿素载体1 (TgUUT1) 容易吸收尿素和尿素.
- TgUUT1对 uracil 和 uridine 都表现出很高的亲和力,但不包括 5-甲基替代物.
- 含金胺,包括5F-uracil和5F,2'-deoxyuridine,在体外和体内表现出对*T. gondii*的强有力的抗代谢活性,表现优于硫法.
结论:
- TgUUT1是对*Toxoplasma gondii*进行验证的药物标.
- 针对TgUUT1的新型化pyrimidines代表了一个有前途的新类抗毒素菌药物.
- 这些新药与目前的第一线治疗相比,显示出更高的疗效.
关键词:
5 - 化氨基氨基.5 - - 甲酸是一种5甲.这种毒素虫 (Toxoplasma gondi) 是一种毒素.这是一种抗代谢物质.类皮里米丁的含量是多少皮里米丁的救援工作乌拉西尔的传送器尿素运输 尿素运输更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...